Top 10 Most Impactful AI Bio Companies in Mid-2026: A Field Guide

The AI-bio field has 331 companies in the curated AI-bio directory, but only about ten of them actually matter in mid-2026. Below is a field guide to those ten — what each does, who backs them, where they are clinically, and how the deals stack up. The ranking is built on a 6-axis rubric (pipeline maturity, capital base, big-pharma validation, technical differentiation, AI-native architecture, and real-world impact).

This is the short list. The long tail — the 320+ companies with no clinical assets, no pharma validation, and under $50M raised — is real, important for diversity, and not yet impactful. The catalyst calendar in H2 2026 will likely shuffle the top 10, but the current incumbents are durable for at least the next 12 months.

1. Isomorphic Labs — Alphabet / DeepMind

The only AI-bio company with a frontier science foundation (AlphaFold 3), a $3B+ pharma partnership portfolio, and a sovereign balance sheet. The first Isomorphic-designed small molecules from its Lilly and Novartis collaborations are projected to enter Phase 1 in late 2026 — the first real-world test of whether AlphaFold-class methods can move into the clinic.

Axis	Detail
Status	Private; Alphabet subsidiary (founded 2021 as DeepMind spinoff)
HQ	London, UK
Capital	~$2.1B raised (Series B, May 2026); Alphabet-backed
Partnerships	Novartis, Eli Lilly (~$3B combined deal value), Johnson & Johnson
AI focus	Generative drug design; AlphaFold 3; molecular property prediction; structure-based design
Clinical status	First IND filings projected late 2026

The bet: AlphaFold was a 2021 research breakthrough. Isomorphic is the bet that the same group can convert that breakthrough into clinical assets — with Eli Lilly and Novartis as the distribution channel. If the Phase 1 readouts in late 2026/early 2027 work, the entire AI-bio thesis gets validated at the same time.

2. Insilico Medicine (HKEX: 3696)

The most aggressive deal-making machine in AI bio right now. Public since December 30, 2025 on HKEX (~$293M IPO). Three back-to-back major pharma deals in 7 months: $100M+ Eli Lilly (November 2025), $888M Servier oncology (January 2026), $2.5B SK Biopharmaceuticals neuroimmune (June 22, 2026 — five days before this post). Combined deal value $3.5B+. INS018_055 (Phase 2 IPF) is the most-advanced AI-discovered small molecule anywhere. Approximately 20 clinical or IND-enabling assets total.

Axis	Detail
Status	Public, HKEX: 3696 (IPO Dec 30, 2025)
HQ	Cambridge, MA / Hong Kong / Shanghai
Capital	~$293M IPO + ~$400M prior private raises; ~HKD 40 share price Jun 2026
Partnerships	Eli Lilly ($100M+, Nov 2025); Servier ($888M, Jan 2026); SK Biopharmaceuticals ($2.5B, Jun 2026); Qilu Pharmaceutical ($120M metabolic); historical deals with Pfizer, Roche, Novartis, J&J
AI focus	End-to-end platform: target identification (PandaOmics) → generative chemistry (Chemistry42) → clinical trial prediction (InClinico); foundation models for biology
Clinical status	INS018_055 Phase 2 IPF (positive Phase 2a); MEN2501 KIF18A inhibitor Phase 1 via Menarini Group; 20+ clinical or IND-enabling assets

The bet: “AI-first pharma” at scale. Every step from target → molecule → clinical design uses Insilico’s platform. The string of back-to-back pharma deals in late 2025 / early 2026 is the strongest evidence yet that the model works as a repeatable deal-making engine. The Phase 2b INS018_055 readouts in 2026-2027 will determine whether the clinical bet also works.

3. Recursion Pharmaceuticals (NASDAQ: RXRX)

Acquired Exscientia in November 2024 for $688M all-stock, creating the largest pure-play AI drug discovery platform by clinical assets (10 clinical-stage programs: 7 from Recursion + 3 from Exscientia). Combines Recursion’s industrial-scale phenotypic biology with Exscientia’s precision chemistry. Recursion OS is one of the largest proprietary biological datasets in pharma (50+ PB).

Axis	Detail
Status	Public, NASDAQ: RXRX
HQ	Salt Lake City, UT
Capital	~$850M cash at merger close; targeting $100M partnership inflows by end-2026; runway through Q4 2027
Partnerships	Sanofi (small molecule, survived merger), Roche/Genentech (small molecule), Bayer (oncology), historical Takeda
AI focus	Phenomics + generative chemistry (post-Exscientia); Recursion OS combines automated biology, chemistry, ML
Clinical status	10 clinical-stage programs including REC-1245 (RBM39 degrader) — favorable Phase 1 safety/PK reported Q1 2026

The bet: Industrial-scale biology + AI-driven chemistry can run more shots on goal per dollar than any other platform. The pipeline trim in 2025 (post-merger) signaled discipline; the Q1 2026 REC-1245 data was the first real clinical proof point.

4. Valo Health — Flagship Pioneering

Flagship’s data-first AI bio company, with a $3B+ Merck KGaA Parkinson’s deal (November 2025) — one of the largest single AI-bio partnerships in history. CEO Brian Alexander (ex-Foundation Medicine CEO, ex-Roche/Genentech SVP) brings serious clinical-development credibility. Valo’s Opal platform uses 17M+ patient records with closed-loop chemistry. Previous $750M cash from SPAC.

Axis	Detail
Status	Private; Flagship Pioneering company
HQ	Boston, MA
Capital	~$750M cash from SPAC (2021); $3B+ biobucks from Merck KGaA
Partnerships	Merck KGaA ($3B+ Parkinson’s, Nov 2025); Pfizer/Flagship autoimmune (multi-billion); Charles River (Logica platform)
AI focus	Human causal biology; 17M+ patient records; closed-loop chemistry; Opal + Logica platforms
Clinical status	Internal pipeline with two programs; partnered programs in Parkinson’s and autoimmune

The bet: Human causal biology — connect genotype + phenotype + clinical outcomes across 17M patients, find causal drivers of disease, design against them. The Merck KGaA deal at $3B+ is the strongest external validation of any AI-bio company’s data-platform thesis.

5. Schrödinger, Inc. (NASDAQ: SDGR)

The longest-running AI-bio platform in the public markets (founded 1990, IPO 2020). Physics-based molecular simulation (force-field methods) combined with ML has been validated through repeated out-licensing and a robust cash position. The 2026 strategic priorities explicitly emphasize the physics+AI platform as the differentiator vs. pure-LLM peers.

Axis	Detail
Status	Public, NASDAQ: SDGR
HQ	New York, NY
Capital	Multi-hundred-million cash balance; profitable on operating basis in some years
Partnerships	Many — historical collaborations with most top-10 pharmas
AI focus	Physics-based molecular simulation + ML; force-field methods; free-energy perturbation; LiveDesign platform
Clinical status	Owns several wholly-owned clinical assets (e.g., SGR-1505 MALT1 inhibitor); also out-licensed programs

The bet: LLMs are stochastic; physics-based methods are deterministic. Schrödinger’s bet is that the next decade of drug discovery will be won by companies that keep the deterministic physics substrate front-and-center and add ML as the interface, not the engine.

6. Insitro

Daphne Koller’s company (Coursera co-founder, Stanford) is the most science-rigorous of the major AI bio companies. Expanded its Bristol Myers Squibb collaboration for ALS in March 2026 (additional targets via its Virtual Human™ platform); acquired CombinAbleAI in January 2026 to complete a modality-agnostic full stack (small molecules + oligos + antibodies + complex biologics).

Axis	Detail
Status	Private
HQ	South San Francisco, CA
Capital	$643M+ raised; Series D expected 2026
Partnerships	Bristol Myers Squibb (5-year ALS/FTD discovery collaboration, expanded 2026); Gilead; previously Eli Lilly
AI focus	Causal biology; iPSC-derived disease models at scale; ML on phenotypic data; POSH platform (Nature Communications)
Clinical status	Pre-clinical to IND-enabling; multiple programs in CNS/ALS, metabolic disease, oncology

The bet: “Causal biology” — using ML on iPSC-derived cells to find the actual causal drivers of disease rather than just phenotypic correlates. The CombinAbleAI acquisition closed the loop from target → modality selection → molecule design in a single platform.

7. Generate:Biomedicines

Flagship Pioneering’s generative biology platform. ~$1B Novartis deal (announced 2024, with $50M upfront + $15M equity investment; $1B+ biobucks). Pfizer, Lilly, and Shionogi partnerships also active. Their foundation protein model (Chroma, released 2022) is one of the open foundational contributions of the field. Generate has been dosing the first patient in SOLAIRIA-1, the first pivotal Phase 3 trial of a fully AI-designed antibody (GB-0895, anti-TSLP for severe asthma).

Axis	Detail
Status	Private; Flagship Pioneering company
HQ	Cambridge, MA
Capital	$400M+ raised; Flagship-backed
Partnerships	Novartis (~$1B biobucks); Pfizer; Eli Lilly; Shionogi
AI focus	Generative protein design — foundation protein models (Chroma); high-throughput wet-lab validation; design-build-test-learn loop
Clinical status	SOLAIRIA-1 Phase 3 (GB-0895 anti-TSLP) first patient dosed; multiple partnered programs

The bet: Biology-as-engineering. Generate’s argument is that proteins can be designed from first principles (sequence → structure → function), and that the wet-lab validation loop is fast enough to train on real experimental data rather than relying on public corpora. The Novartis deal validates the model at scale; SOLAIRIA-1 is the first clinical proof of concept.

8. Tempus AI (NASDAQ: TEM)

The only large-scale commercial AI-on-clinical-data platform at public-market scale. Multimodal foundation models in oncology; FDA-cleared ECG-AI; partner with Artera for AI prostate test. Strong Q1 2026 revenue growth and raised full-year guidance. Tempus has also been an active AI-bio consolidator — its 2025 acquisition of Paige AI (cancer pathology) folded a competitor into the platform.

Axis	Detail
Status	Public, NASDAQ: TEM
HQ	Chicago, IL
Capital	Multi-billion market cap; strong revenue (data licensing + diagnostics)
Partnerships	Many — Artera (prostate AI), pharma data licensing, NIH, academic centers; acquired Paige AI (2025)
AI focus	Multimodal foundation models (imaging + pathology + molecular + clinical); ECG-AI; computational pathology
Clinical status	FDA-cleared products; ~$1B+ annual revenue run-rate

The bet: AI for biology is downstream of AI for clinical data. Tempus has the largest proprietary oncology dataset in the US (millions of patients with molecular + outcome data), and the FDA clearance flywheel lets them monetize the data while building the AI. Different category from the wet-lab-first companies above, but arguably the larger commercial impact already.

9. Iambic Therapeutics

Clinical-stage AI drug discovery with $334M+ raised across 5 rounds; $1.7B biobucks deal with Takeda announced 2025; oversubscribed $100M+ Series C extension in late 2025 with Mubadala + Qatar Investment Authority. Lead asset IAM1363 (brain-penetrant HER2 inhibitor) in Phase 1/1b with favorable preclinical data; CDK2/4 and KIF18A programs advancing. Their NeuralPLexer protein-ligand structure-prediction model was featured on a Nature Machine Intelligence cover article in 2026.

Axis	Detail
Status	Private; clinical-stage
HQ	San Diego, CA
Capital	$334M+ raised
Partnerships	Takeda (up to $1.7B biobucks)
AI focus	Physics-informed neural networks (NeuralPLexer encoder/decoder); multi-modal AI for chemistry; own foundational models for molecular design
Clinical status	IAM1363 Phase 1/1b (HER2-mutant and HER2-amplified tumors, including intracranial); CDK2/4 inhibitor; KIF18A allosteric inhibitor; multiple undisclosed programs

The bet: IAM1363 is “among the first AI-designed small molecules worldwide to reach clinical stage, validating Iambic’s computational-to-clinical translation capability.” The Takeda deal is the largest single AI-bio pharma partnership of 2025.

10. Biolojic Design

The company that put the first AI-designed antibody in Phase 2 clinical trials — AU-007 (anti-IL-2 for solid tumors) — a historic milestone for the AI-bio field. $376M (€346M) Merck KGaA deal (June 2024) for multi-specific antibodies; Teva partnership (TEV-325, preclinical milestone reached March 2026); BD200 (anti-cancer AI-designed antibody) advancing to Phase 2. Israeli computational biology company.

Axis	Detail
Status	Private
HQ	Tel Aviv, Israel
Capital	~$50M raised historically; deal economics dominate (Merck KGaA $376M, Teva)
Partnerships	Merck KGaA ($376M / €346M, Jun 2024); Teva (TEV-325 milestone, Mar 2026); Nektar Therapeutics
AI focus	Computational antibody design; “smart antibodies” with programmable switches (agonism, antagonism, conditional binding); multibody design
Clinical status	AU-007 (Phase 2, solid tumors, first AI-designed antibody in Phase 2); BD200 (Phase 2, cancer); TEV-325 (preclinical milestone, autoimmune)

The bet: AI-designed antibodies can be “smart” — built as programmable switches with conditional binding, agonism, antagonism built in. AU-007 in Phase 2 is the first clinical proof that computationally designed antibodies can move from in silico to humans.

The Cohort Behind the Top 10 (Notable Runners-Up)

These companies didn’t crack the top 10 by the rubric but deserve mention as the next tier of high-impact AI bio:

#	Company	Why notable
11	Xaira Therapeutics	$1B committed funding at launch (April 2024) — largest AI-bio launch to date; ARCH Venture Partners + Foresite Capital; CEO Marc Tessier-Lavigne (former Genentech CSO, Denali co-founder); foundation models for generative drug design
12	XtalPi (HKEX: 2228)	Public; quantum physics + AI + robotics; $400M+ strategic partnership (Jun 2026); 10-15% AI-drug-development market share; Lilly $345M bispecific antibody deal via Ailux Biologics subsidiary
13	Formation Bio	$372M Series D (Jun 2024) led by a16z with Sanofi participation; Sequoia, Thrive, Emerson Collective; “AI-native pharma” model (in-license + AI-develop)
14	Genesis Therapeutics	NVIDIA + Incyte ($80M, May 2026) + Gilead partnerships; Pearl + GEMS foundation models
15	PostEra	$1B+ total AI partnerships (Pfizer $610M, Amgen, NIH); Proton platform; small molecule AI
16	AbCellera (NASDAQ: ABCL)	$655M cash; clinical-stage antibody platform; positive Phase 1 interim for ABCL635 (NK3R for hot flashes, May 2026)
17	Absci (NASDAQ: ABSI)	De novo generative antibody design; clinical-stage; partnered with Owkin and Twist
18	Profluent	$106M raised; OpenCRISPR gene-editing foundation model; Berkeley-based
19	Cradle	$103M+ raised; protein engineering foundation model; Novartis + Schrodinger partnerships
20	Lila Sciences	$550M raised; $1.3B valuation; Flagship Pioneering’s “scientific superintelligence” autonomous labs
21	BenchSci	$197M raised; $95M Series D (Generation IM); ASCEND AI platform for R&D transformation
22	Deep Genomics	$180M Series C; AI Workbench platform; RNA therapeutics for genetic diseases
23	Owkin	AstraZeneca partnership (breast cancer AI); Anthropic partnership for Pathology Explorer agent (Jan 2026)
24	CytoReason	$80M from OurCrowd + NVIDIA + Pfizer + Thermo Fisher; AI disease models
25	Variational AI	$349M Merck & Co deal (Enki platform, two targets); Vancouver-based; Enki 4 foundation model released May 2026
–	PathAI	Acquired by Roche for up to $1.05B (announced May 7, 2026; $750M upfront + $300M milestones) — now a Roche subsidiary
–	Exscientia	Acquired by Recursion (~$688M all-stock, Nov 2024) — now part of RXRX

Cross-Cutting Observations

1. The 2025-2026 AI-bio M&A wave is the largest signal of the field’s maturity. Roche’s $750M-$1.05B acquisition of PathAI (May 2026) is the single largest diagnostic-AI acquisition to date. Tempus AI’s 2025 acquisition of Paige AI (cancer pathology) and Recursion’s $688M acquisition of Exscientia (November 2024) round out the picture. The pattern: big-pharma and large-platform players are absorbing AI-bio companies at scale rather than building from scratch.

2. The Insilico “deal machine” is the new baseline. Three pharma deals totaling $3.5B+ in 7 months — Lilly ($100M+), Servier ($888M), SK Bio ($2.5B) — combined with the HKEX IPO and 20+ clinical assets. The Insilico playbook (AI-discover → pharma-develop → platform-scale) is the one to watch for the rest of 2026.

3. The frontier-model cohort is small but growing. Isomorphic Labs, Generate, Profluent, Latent Labs, Cradle, EvolutionaryScale, BigHat are the frontier-model companies. Of these, only Isomorphic and Generate have signed billion-dollar pharma deals. The next 5 frontier-model companies that crack billion-dollar deals will likely come from this list.

4. The clinical proof point is now real. The four most-advanced AI-designed molecules in the clinic as of mid-2026: INS018_055 (Insilico, Phase 2 IPF, positive Phase 2a); REC-1245 (Recursion, Phase 1 RBM39, positive Q1 2026); IAM1363 (Iambic, Phase 1 HER2); AU-007 (Biolojic Design, Phase 2 solid tumors — first AI-designed antibody in Phase 2). The Phase 2/3 readouts in 2026-2027 will define whether the AI-bio thesis works or doesn’t.

5. Big-pharma partnerships are concentrated at the top. Insilico ($3.5B+ with Lilly + Servier + SK Bio), Isomorphic ($3B+ with Novartis + Lilly + J&J), Valo ($3B with Merck KGaA), Generate ($1B+ with Novartis), Iambic ($1.7B with Takeda), Insitro (BMS), PostEra ($1B+ total), Recursion (Sanofi + Roche/Genentech + Bayer). The “AI partner of choice” decision at each top-10 pharma is consolidating around 5-10 companies.

6. First-in-class clinical milestones matter as much as deal size. Biolojic Design’s AU-007 (first AI-designed antibody in Phase 2) and Insilico’s INS018_055 (first AI-discovered AI-designed small molecule in Phase 2) are the two “first-in-class” milestones that reframe the entire field. Generate Biomedicines’ SOLAIRIA-1 first patient dosing (Phase 3 anti-TSLP) is the first Phase 3 milestone.

7. The 2026 catalyst calendar is dense. Phase 1/2 readouts expected in H2 2026: INS018_055 Phase 2b (Insilico), REC-1245 Phase 1 efficacy (Recursion), IAM1363 Phase 1 (Iambic), ABCL635 Phase 2 (AbCellera), BigHat ADC Phase 1, MEN2501 Phase 1 (Insilico/Menarini). A single positive Phase 2 readout in late 2026 / early 2027 would re-rank the top 10.

What to Watch Over the Next 6 Months

• Late Q3 2026 — rentosertib Phase 3 initiation. If Insilico hits this milestone on time, rentosertib becomes the most-watched AI-drug clinical asset globally. First interim data ~2028.
• Q4 2026 — Isomorphic Labs Phase 1 IND. The first AlphaFold-3-class designed small molecule reaching the clinic. If the IND lands on time, the AI-bio thesis gets a flagship validation event.
• Q1 2027 — SOLAIRIA-1 interim look. Generate’s first Phase 3 interim efficacy readout will be the first major efficacy data point for an AI-designed antibody.
• Throughout 2026-2027 — second-tier AI-bio consolidation. Expect 5-10 mid-cap AI-bio companies (Pathos, Cradle, Iambic, smaller Recursion peers) to either raise down rounds, get acquired by pharma, or pivot to platform-only models.
• H2 2026 — open-source activity-prediction release. If Boltz-2 or a peer publishes a model that closes the gap on FEP-grade affinity prediction, the commercial structure-prediction market collapses further.

The Bottom Line

The AI-bio field has 331 companies in the curated directory, but the top 10 are well-defined. Insilico’s three-deal-in-seven-months run is the deal-making benchmark. Isomorphic’s AlphaFold-3-to-clinic transition is the technical benchmark. Recursion + Exscientia’s combined pipeline is the clinical-stage benchmark. Valo’s Merck KGaA partnership is the data-platform benchmark. Schrödinger’s 30-year compounding is the durability benchmark. Insitro’s causal-biology + multi-modality stack is the science benchmark. Generate’s SOLAIRIA-1 is the antibody benchmark. Tempus’s data flywheel is the commercial benchmark. Iambic’s Takeda deal is the small-molecule benchmark. Biolojic’s AU-007 is the first-in-class clinical milestone.

The companies that will survive 2026-2027 are the ones that combined (a) AI capability, (b) proprietary wet-lab or clinical-data loops, (c) at least one clinical-stage asset, and (d) commercial pharma partnerships. The 320+ companies below the cutoff are mostly missing at least one of those four — and that’s a structural problem, not a tactical one.

The next re-rank will be triggered by clinical readouts in late 2026 / early 2027, not by additional funding rounds. The capital story is mostly told. The clinical story is just beginning.

---

Sources: Insilico Medicine + SK Biopharmaceuticals press release (June 22, 2026); Insilico Medicine + Eli Lilly partnership (November 2025); Insilico Medicine + Servier partnership (January 2026); Insilico Medicine HKEX IPO prospectus (December 30, 2025); Isomorphic Labs Series B coverage (Forbes, May 2026); Recursion Pharmaceuticals Q1 2026 financial results; Recursion-Exscientia merger (November 2024); Valo Health + Merck KGaA press release (November 20, 2025); Schrödinger 2026 strategic priorities (January 12, 2026); insitro + Bristol Myers Squibb expansion (March 23, 2026); insitro-CombinAbleAI acquisition (January 12, 2026); Generate:Biomedicines + Novartis deal (FierceBiotech); Iambic Therapeutics Series B/C extension + Takeda deal; Biolojic Design + Merck KGaA (June 2024); Biolojic Design AU-007 Phase 2 milestone; Tempus AI Q1 2026 earnings; PathAI-Roche acquisition (WSJ, May 2026); weekly industry-diff research sweep of 331 curated AI-bio companies (this session); company press releases, SEC filings, and peer-reviewed publications across all ten companies.